| Q39157770 | 123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy |
| Q57057499 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines |
| Q35553674 | A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats |
| Q57301157 | Advanced imaging modalities to detect cardiotoxicity |
| Q91757097 | Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment |
| Q45268606 | Assessment of an intermediate reprojection technique transitioning from planar to SPECT radionuclide ventriculography |
| Q39053477 | Biomarkers for monitoring chemotherapy-induced cardiotoxicity |
| Q38025824 | Cancer drugs and the heart: importance and management |
| Q38735433 | Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions |
| Q30415201 | Cardiac complications of chemotherapy: role of imaging |
| Q30446453 | Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction |
| Q39185620 | Cardio-oncology: the Nuclear Option |
| Q38343043 | Cardiotoxicity due to chemotherapy: role of cardiac imaging. |
| Q24628695 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management |
| Q38225977 | Cardiotoxicity of antineoplastic agents: what is the present and future role for imaging? |
| Q41704131 | Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment |
| Q37430831 | Cardiovascular toxicity caused by cancer treatment: strategies for early detection |
| Q38580452 | Chemotherapy-induced cardiomyopathy |
| Q38844387 | Comprehensive review on cardio-oncology: Role of multimodality imaging |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q28083073 | Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors |
| Q36210537 | Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography |
| Q93001734 | Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy |
| Q37116520 | Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). |
| Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
| Q57682319 | EANM/ESC guidelines for radionuclide imaging of cardiac function |
| Q42706690 | Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion |
| Q38909573 | Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure |
| Q37560059 | Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study |
| Q30401812 | Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging |
| Q37372203 | Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk |
| Q50101800 | Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity |
| Q50999891 | How could we solve the diagnostic dilemma of doxorubicin toxicity in high-risk patients? |
| Q38197733 | Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction |
| Q36496257 | Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging |
| Q30427656 | Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs |
| Q33942611 | Nuclear imaging in detection and monitoring of cardiotoxicity |
| Q40575681 | Pre-chemotherapy values for left and right ventricular volumes and ejection fraction by gated tomographic radionuclide angiography using a cadmium-zinc-telluride detector gamma camera. |
| Q27007849 | Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients |
| Q43262768 | Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer. |
| Q51786328 | Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. |
| Q47909593 | The motivation to reproject gated blood pool SPECT data as planar data |
| Q52982588 | The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. |
| Q53392128 | The time for radionuclide ventriculography resurrection is coming. |
| Q81086247 | Topoisomerase II inhibitors |
| Q38097736 | Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively |
| Q38069202 | Using cardiac biomarkers and treating cardiotoxicity in cancer |
| Q51064268 | Utility of reprojected tomograms. |